

An In-Depth Review of SAPHNELO: Results From the TULIP Pivotal Trials, 4-Year LTE and Emerging Data



PRESENTED BY: **Grace Wright, MD PC**Clinical Associate Professor of Medicine
New York, NY





This program/event is developed and offered by AstraZeneca. This is not an official program/event of the Cleveland Clinic.



Scan here for full Prescribing Information, including Patient Information, or visit SAPHNELOPI.com.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.



This program is intended for US healthcare professionals only.

AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. This is a presentation sponsored directly by AstraZeneca and there are no continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credits associated with this activity. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits. SAPHNELO is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca. All rights reserved. US-98162 2/25